2-(2-Methylsulfonylethyl)quinoxaline | 1146222-10-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-(2-Methylsulfonylethyl)quinoxaline
• CAS: 1146222-10-7
• 化学式: C₁₁H₁₂N₂O₂S
• 分子量: 236.294
• InChiKey: RGEYYMKCGFRZQZ-UHFFFAOYSA-N

物化性质

• 沸点：
  452.8±35.0 °C(predicted)
• 密度：
  1.310±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  68.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-乙烯基喹喔啉 、 sodium methansulfinate 在 三氟乙酸 作用下， 以 乙醇 为溶剂， 反应 6.0h， 以91%的产率得到2-(2-Methylsulfonylethyl)quinoxaline
  参考文献：
  名称：

  将甲磺酸钠共轭添加到乙烯基吡啶和二嗪中以合成脂肪族砜

  摘要：

  描述了将砜基引入吡啶和二嗪的简便方法。这种有效的方法涉及将亚磺酸钠共轭加成到乙烯基杂环上。该方法可耐受多种官能团，并且在乙酸或三氟乙酸的存在下进行。还描述了从相应的杂芳基卤化物开始的一锅，两步合成砜。

  DOI：

  10.1016/j.tetlet.2009.02.037

文献信息

• Alpha ketoamide compounds as cysteine protease inhibitors
  申请人：Graupe Michael

  公开号：US20070021353A1

  公开（公告）日：2007-01-25

  The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

  本发明涉及一种抑制半胱氨酸蛋白酶的化合物，特别是对卡特普西蛋白B、K、L、F和S的抑制剂，因此可以用于治疗由这些蛋白酶介导的疾病。本发明涉及包含这些化合物的制药组合物和制备它们的方法。
• Sulfonyl Containing Compounds as Cysteine Protease Inhibitors
  申请人：Mossman Craig J.

  公开号：US20080287446A1

  公开（公告）日：2008-11-20

  The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

  本发明涉及抑制半胱氨酸蛋白酶的化合物，特别是猫蛋白酶B、K、L、F和S，因此在治疗由这些蛋白酶介导的疾病方面非常有用。本发明涉及包含这些化合物的制药组合物和制备它们的方法。
• SULFONYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS
  申请人：Mossman Craig

  公开号：US20110281879A1

  公开（公告）日：2011-11-17

  The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

  本发明涉及抑制半胱氨酸蛋白酶的化合物，特别是抑制B、K、L、F和S型蛋白酶，因此在治疗由这些蛋白酶介导的疾病中有用。本发明涉及包含这些化合物的制药组合物和其制备方法。
• ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS
  申请人：Graupe Michael

  公开号：US20120190714A1

  公开（公告）日：2012-07-26

  The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

  本发明涉及一种抑制半胱氨酸蛋白酶的化合物，特别是抑制B、K、L、F和S型猫蛋白酶，因此在治疗由这些蛋白酶介导的疾病方面有用。本发明涉及包含这些化合物的制药组合物和制备它们的方法。
• US7488848B2
  申请人：——

  公开号：US7488848B2

  公开（公告）日：2009-02-10